Corvus Pharmaceuticals, Inc..
CRVS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies that modulate the immune system to treat patients with cancer. The company's lead product candidate is CPI-444, an adenosine A2A receptor antagonist, which i...Show More
Better Health for All
0
No evidence available to assess Corvus Pharmaceuticals, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Corvus Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data was found across the provided articles to assess Corvus Pharmaceuticals, Inc. against any of the Fair Pay & Worker Respect KPIs. While the CEO's total compensation for 2023 was reported as $1,321,351, the median employee compensation was not provided, preventing the calculation of the CEO-to-median pay ratio.
1
Employee satisfaction with compensation and benefits was rated 3.8/5 stars, but this is specific to benefits and not an overall employee engagement or satisfaction index as required by the rubric.
2
No other quantitative data for living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage was available.
3
Fair Trade & Ethical Sourcing
0
The provided articles, primarily annual reports, do not contain specific, concrete data points for any of the KPIs related to Fair Trade & Ethical Sourcing. There is no information available regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
1
Honest & Fair Business
0
No evidence was found in the provided articles to assess Corvus Pharmaceuticals, Inc. against the 'Honest & Fair Business' ethical value. The article content was inaccessible, preventing the extraction of any relevant data for the specified KPIs.
1
Kind to Animals
-60
Corvus Pharmaceuticals conducts animal studies using syngeneic mouse tumor models and rats to evaluate drug efficacy and safety.
1
These studies are performed in accordance with an Institutional Animal Care and Use Committee (IACUC) and the American National Research Council’s Guide for the Care and Use of Laboratory Animals.
2
The company utilizes various mouse models for diseases such as systemic sclerosis, prostate cancer, acute graft-versus-host disease, autoimmune lymphoproliferative syndrome, and non-small cell lung cancer.
3
While specific total animal volumes are not provided, the research involves multiple models and experiments, including administering CPI-444 at 1, 10, or 100 mg/kg for 28 days, and soquelitinib at doses up to 1000 mg/kg/day in rats and 10-300 mg/kg/day in mice for several days.
4
The company's policy is to comply with standard ethical guidelines for animal research, but there is no evidence of a policy to reduce or eliminate animal testing, nor any transparent reduction targets for animal usage.
No War, No Weapons
0
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies.
1
The provided articles, including the annual report, contain no evidence of the company engaging in any activities related to arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, or any other defense-related business. As no specific, concrete data points are available for any of the KPIs, all KPIs are omitted from the scoring.
Planet-Friendly Business
0
No specific, concrete data points for Corvus Pharmaceuticals, Inc. (CRVS.US) were found across the provided articles for any of the Planet-Friendly Business KPIs. explicitly states that sustainability data is currently unavailable for the company.
1
Other articles either provided industry-level information without company-specific details or did not contain relevant data.
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess Corvus Pharmaceuticals, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' ethical value.
1
The articles focused on company culture and governance documents, without providing data on community engagement, cultural impact, or related initiatives.
Safe & Smart Tech
0
The company has implemented a cybersecurity risk management program that includes risk assessments, a security team, external service providers for security control assessment and testing, and a cybersecurity incident response plan.
1
Cybersecurity awareness training is provided to employees, incident response personnel, and senior management.
2
The Board of Directors, through its Audit Committee, oversees cybersecurity and IT risks, with the Chief Financial Officer responsible for assessing and managing material cybersecurity threats.
3
The company states that it has not identified risks from known cybersecurity threats, including prior incidents, that have materially affected or are reasonably likely to materially affect its operations, business strategy, results of operations, or financial condition.
4
The company is subject to various state, federal, and foreign laws governing the collection, dissemination, use, access, confidentiality, and security of personal and health-related information.
5
Zero Waste & Sustainable Products
0
The company, as a subtenant, is required to comply with its Master Lease and Prime Sublease regarding the use, presence, storage, release, or disposal of hazardous materials.
1
This includes storing hazardous waste in a designated Bio Waste Room 1306 and surrendering the sublease premises free of hazardous materials stored, used, released, or disposed of by the subtenant.
2
The company also pays for non-hazardous waste collection service.
3